Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignancies after kidney transplantation.

M Rascente1, F Pisani, A Barletta

  • 1U.O. Trapianti, Dipartimento di Scienze Chirurgiche, Università L'Aquila, Coppito, Italy.

Transplantation Proceedings
|September 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anomalous mass diffusion in a binary mixture and Rayleigh-Bénard instability.

Physical review. E·2024
Same author

Improved Measurement of CP Violation Parameters in B_{s}^{0}→J/ψK^{+}K^{-} Decays in the Vicinity of the ϕ(1020) Resonance.

Physical review letters·2024
Same author

Measurement of CP Violation in B^{0}→ψ(→ℓ^{+}ℓ^{-})K_{S}^{0}(→π^{+}π^{-}) Decays.

Physical review letters·2024
Same author

Diabetes and perio screening.

British dental journal·2024
Same author

Observation of New Baryons in the Ξ_{b}^{-}π^{+}π^{-} and Ξ_{b}^{0}π^{+}π^{-} Systems.

Physical review letters·2023
Same author

Precision Measurement of CP Violation in the Penguin-Mediated Decay B_{s}^{0}→ϕϕ.

Physical review letters·2023

Kidney transplant recipients have a 3% cancer prevalence. Long-term immunosuppression increases malignancy risk, but careful pre-transplant screening and reduced immunosuppression may lower cancer rates in these patients.

Area of Science:

  • Nephrology
  • Oncology
  • Immunology

Background:

  • Renal transplantation is the optimal treatment for end-stage renal disease, significantly improving patient longevity.
  • Advances in immunosuppression have enhanced patient and graft survival but are linked to increased cancer incidence.

Purpose of the Study:

  • To determine the prevalence of de novo malignancies in kidney transplant recipients.
  • To analyze the relationship between duration of immunosuppression and cancer development.

Main Methods:

  • Retrospective analysis of 265 kidney transplant recipients engrafted between 1968 and October 2004.
  • Categorization of patients based on duration of immunosuppression (<3 years vs. >3 years).

Main Results:

Related Experiment Videos

  • Overall de novo malignancy prevalence was 3%.
  • Patients with >3 years of immunosuppression had a 5% cancer rate (vulva, colon, native kidneys, prostate, ovary), including one de novo transplant kidney carcinoma.
  • One patient (0.8%) with <3 years of immunosuppression developed post-transplantation lymphoproliferative disorder (PTLD).

Conclusions:

  • The study observed a low early cancer prevalence, potentially due to pre-transplant screening, HLA matching, and avoidance of anti-T-cell therapy.
  • Long-term immunosuppression is associated with an increased risk of malignancy, consistent with other reports.
  • Minimizing immunosuppression may contribute to a lower incidence of neoplasia post-transplantation.